Phase 1b Multicenter Double-Blind Placebo-Controlled Study on Safety, Tolerability, and Efficacy of si-544 in Psoriasis Vulgaris and Psoriatic Arthritis

The primary objective of this multicenter, Phase 1b, double-blind, placebo-controlled study is to evaluate the **safety** and **tolerability** of si-544 in adults diagnosed with **psoriasis vulgaris** or **psoriatic arthritis**. Assessing the safety profile is clinically relevant as it determines the potential risks associated with si-544, ensuring that it is safe for further clinical development. Evaluating tolerability is crucial to understand how well patients can endure the treatment, which is essential for long-term management of these chronic conditions.

The clinical trial involves participants diagnosed with **psoriasis vulgaris** and **psoriatic arthritis**. The study population includes both male and female subjects, with an age range corresponding to categories 3 and 4, which typically represent adults and older adults. The trial population was selected to include a vulnerable population, although specific details regarding the selection process or lifestyle considerations such as diet or physical activity are not provided. The sponsor has not disclosed the total number of participants involved in the study.

The clinical trial is a **Phase 1b**, double-blind, placebo-controlled study designed to evaluate the safety, tolerability, and efficacy of si-544 in adults diagnosed with **psoriasis vulgaris** or **psoriatic arthritis**. The trial is structured as a multicenter study, ensuring a diverse participant pool and robust data collection. The trial is expected to commence recruitment on December 1, 2023, and is projected to conclude by January 31, 2025, providing a comprehensive evaluation period.

Participants will undergo a series of study visits, beginning with an inclusion visit, also known as the screening visit, to assess eligibility based on predefined criteria. Following successful screening, participants will be randomized into either the treatment or placebo group, maintaining the double-blind nature of the study. Throughout the trial, participants will attend regular follow-up visits to monitor safety, tolerability, and any adverse events, as well as to assess the efficacy of the investigational product. The end-of-study visit will mark the conclusion of the participant's involvement, where final assessments will be conducted to gather comprehensive data on the trial's outcomes.

The expected duration of participant involvement will span the entire trial period, from the initial screening to the end-of-study visit. However, certain conditions may necessitate early termination from the study, such as the occurrence of significant adverse events, non-compliance with study protocols, or withdrawal of consent by the participant. The trial's design and procedures are meticulously crafted to ensure the collection of high-quality data while prioritizing participant safety and adherence to ethical standards.

In this clinical trial, the experimental medication and non-experimental treatments have not been specified in the provided data. Therefore, a detailed description of the **experimental medication**, including its name, pharmaceutical form, dosage, route, and frequency of administration, cannot be provided. Similarly, information regarding any non-experimental treatments, such as standard-of-care therapy, placebo, or comparator treatment, is not available.

Due to the absence of specific details, additional relevant information about drug administration, dosing schedules, and participant compliance monitoring cannot be included. The data does not contain any information about the **disease** being studied, the trial's main objective, or any other pertinent details that would typically be included in a clinical trial description.

The clinical trial is designed to assess efficacy in a Phase 3 study. The trial is scheduled to commence recruitment on December 1, 2023, with an estimated completion date of January 31, 2025. The efficacy assessment will be conducted using predefined parameters, although specific endpoints and methods for measuring efficacy are not detailed in the available data. The trial will follow a structured timeline to ensure systematic data collection and analysis. The focus will be on evaluating the treatment's impact over the course of the study, adhering to rigorous clinical standards. The trial's design and execution will align with the regulatory requirements for Phase 3 studies, ensuring that the findings are robust and scientifically valid.